Search Results - "Sammartino, J. C."

White cell and platelet content affects the release of bioactive factors in different blood-derived scaffolds by Cabaro, S., D'Esposito, V., Gasparro, R., Borriello, F., Granata, F., Mosca, G., Passaretti, F., Sammartino, J. C., Beguinot, F., Sammartino, G., Formisano, P., Riccitiello, F.

“…Platelet-derived factors are biomaterials that might accelerate healing process in oral, maxillofacial, and several other applications. Release of specific…”
Get full text

Error adjustments for file linking methods using encrypted unique client identifier (eUCI) with application to recently released prisoners who are HIV by Gutman, R., Sammartino, C.J., Green, T.C., Montague, B.T.

“…Incarceration provides an opportunity to test for HIV, provide treatment such as highly active anti‐retroviral therapy, as well as link infected persons to…”
Get full text

Humoral and cellular response before and after the fourth BNT162b2 vaccine dose in patients with solid tumors on active treatment by Lasagna, A., Bergami, F., Lilleri, D., Percivalle, E., Quaccini, M., Comolli, G., Sarasini, A., Sammartino, J.C., Ferrari, A., Arena, F., Cicognini, D., Schiavo, R., Lo Cascio, G., Baldanti, F., Pedrazzoli, P., Cassaniti, I.

Get full text

A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study by Lasagna, A., Agustoni, F., Percivalle, E., Borgetto, S., Paulet, A., Comolli, G., Sarasini, A., Bergami, F., Sammartino, J.C., Ferrari, A., Zavaglio, F., Arena, F., Lilleri, D., Secondino, S., Falzoni, M., Schiavo, R., Klersy, C., Lo Cascio, G., Cavanna, L., Baldanti, F., Pedrazzoli, P., Cassaniti, I.

“…Very few cancer patients were enrolled in coronavirus disease-2019 vaccine studies. In order to address this gap of knowledge, real-world studies are…”
Get full text

Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study by Lasagna, A., Bergami, F., Lilleri, D., Percivalle, E., Quaccini, M., Alessio, N., Comolli, G., Sarasini, A., Sammartino, J.C., Ferrari, A., Arena, F., Secondino, S., Cicognini, D., Schiavo, R., Lo Cascio, G., Cavanna, L., Baldanti, F., Pedrazzoli, P., Cassaniti, I.

“…Although a full course of coronavirus disease 2019 (COVID-19) vaccine is effective in cancer patients, the duration of the protection and the efficacy of a…”
Get full text

Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern by Lasagna, A., Bergami, F., Lilleri, D., Percivalle, E., Quaccini, M., Serra, F., Comolli, G., Sarasini, A., Sammartino, J.C., Ferrari, A., Arena, F., Secondino, S., Cicognini, D., Schiavo, R., Lo Cascio, G., Cavanna, L., Baldanti, F., Pedrazzoli, P., Cassaniti, I.

“…The role and the durability of the immunogenicity of the third dose of vaccine against COVID-19 variants of concern in cancer patients have to be elucidated…”
Get full text

Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up by Lasagna, A., Lilleri, D., Agustoni, F., Percivalle, E., Borgetto, S., Alessio, N., Comolli, G., Sarasini, A., Bergami, F., Sammartino, J.C., Ferrari, A., Zavaglio, F., Arena, F., Secondino, S., Falzoni, M., Schiavo, R., Lo Cascio, G., Cavanna, L., Baldanti, F., Pedrazzoli, P., Cassaniti, I.

“…The durability of immunogenicity of SARS-CoV-2 vaccination in cancer patients remains to be elucidated. We prospectively evaluated the immunogenicity of the…”
Get full text